Bausch Health Companies Shareholder Engagement Presentation Deck
2021 Summary
Revenues
2021 reported revenue growth +5% vs 2020
2021 organic revenue growth¹ +6% vs 2020
High single digits for Salix, Int'l and B+L, double digit for
Solta
Growth from commercial execution and new products as
well as post-COVID recovery
Profitability
FY Adj. EBITDA margin¹ 41%, +10 bps vs 2020
Normalizing sales and marketing spend, R&D
Balance sheet
Strong cash flow from operations and proceeds from
divestiture
Debt paydown of $1.3B in 2021; continued deleverage
8
Highlights
Rifaximin SSD (solid soluble dispersion) and Red-C
(reduction of cirrhosis)
IDP-126 (combination acne) NDA expected 4Q22
BLCO: US launch of XIPERE (macular edema)
Progress towards BLCO IPO
1. Non-GAAP measure. See the Appendix for further information on non-GAAP measures and ratios.
BAUSCH- HealthView entire presentation